Back to search results

Home Exercise for Neurodegenerative Diseases

This study is testing a home exercise program to help individuals with neurodegenerative diseases, specifically those with X-linked adrenoleukodystrophy, improve their walking. The home exercise program focuses on addressing limitations that impact walking. We are looking for 30 participants between 5 and 75 years old. For males, X-linked adrenoleukodystrophy must be confirmed by biochemical or genetic testing. For females, it can be confirmed by biochemical testing, genetic testing, or family history (pedigree analysis). The main goal is to see how much the home exercise program changes your lower body function, measured at 12 weeks. The study status is currently unclear.

Study design
This is an interventional study planning to enroll 30 participants. It is testing a behavioral intervention (home exercise).
What's involved
Participants will engage in a home exercise program. Your lower body function will be measured at the beginning and after 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Changes in lower body function will be measured at 12 weeks after starting the exercise program.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05443906

Home Exercise for Individuals With Neurodegenerative Disease

Recruiting
NAAges 5–75InterventionalTreatment
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
~30 participants
Updated 2026-09-16 on ClinicalTrials.gov
What's tested:Home exercise

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in NeuroQOL lower extremity
Measured over baseline 12 weeks

Conditions

Neurodegenerative Diseases
Leukodystrophy
Ataxia
LBSL
Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder)
Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation
Cerebellar Ataxia
Adrenomyeloneuropathy

Explore related trials

AdrenoleukodystrophyCerebellar ataxiaDegenerative Disease of Nervous System, UnspecifiedLeukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate ElevationDARS2 Gene

NCT05443906

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Kennedy Krieger Institute

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jennifer Keller, PT · PRINCIPAL_INVESTIGATOR · Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Who to contact

Jennifer L Keller, PT, MS
[email protected]
443-923-2716
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The eligibility criteria for males is X-linked adrenoleukodystrophy as determined by biochemical determination or genetic testing.
The eligibility criteria for females is X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis.
The Leukoenceophalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion is a confirmed DARS2 mutation through genetic analysis.
For people with cerebellar ataxia, people with diagnoses of cerebellar damage from stroke, tumor or degeneration will be included. Those with a genetically confirmed cerebellar disorder will be asked to provide their genetic testing to note their particular type of ataxia.
We will also include patients with other neurodegenerative diseases similar to these disorders as determined by chart review and clinical exam.
Able to stand for 30 seconds without upper extremity support
Ambulatory (including use of a cane or a walker)
Able to walk for 2 minutes

Exclusion

Other medical or psychological conditions which in the clinical judgement of the investigator would interfere with acquiring the study information or performing the exercises safely including but not limited to:

What this trial measures

  • Change in NeuroQOL lower extremitybaseline 12 weeks

    Patient reported outcome